The global extended release drugs market is experiencing significant growth, projected to expand at a robust 11% CAGR from 2022 to 2032. With a valuation of USD 48 billion in 2022, the market is ...

Mallinckrodt PLC, an Irish pharmaceutical company with a big footprint and long history in the St. Louis area, will buy U.S.

Discover last week's top S&P 500 healthcare gainers, major market stories, and groundbreaking pharma deals, including weight-loss drug updates.

When the deal closes, Endo will become a wholly owned subsidiary of Mallinckrodt. The combined company will take on a ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Endo, Inc. (OTC: NDOI) and Mallinckrodt plc.

Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ETCompany ParticipantsLaure Park - Senior Vice President ...

Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...

The Mallinckrodt-Endo combination will have approximately 5,700 employees at closing, as well as 17 manufacturing facilities, 30 distribution centers, and an operating footprint primarily located in ...

EAST WHITELAND — Endo, a pharmaceutical company that has its global headquarters in Chester County, is being acquired by ...

Health-care companies fell, but not by as much as the broad market, as traders sought out defensive sectors. Drugmaker Mallinckrodt struck a deal to buy rival Endo, one of the drug makers driven into ...